Respiratory Syncytial Virus Targeting of the Human Airway Epithelium
靶向人类气道上皮的呼吸道合胞病毒
基本信息
- 批准号:8775191
- 负责人:
- 金额:$ 40.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-12-01 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:Admission activityAntiviral AgentsApicalBasal CellBindingCause of DeathCell LineCell surfaceCellsCessation of lifeChildCiliaColumnar CellComplexDataDevelopmentDiagnosisElderlyEpithelialEpithelial CellsGTP-Binding ProteinsGlycosaminoglycansGoalsHealthHela CellsHeparitin SulfateHospitalsHumanInfantInfectionInsectaModelingModificationOligosaccharidesOrganOutcomePopulationPost-Translational Protein ProcessingProcessProtein BindingRNA VirusesResearchRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsRespiratory syncytial virusSiteSurfaceTestingVaccinesVirionVirusVirus DiseasesVirus Receptorsairway epitheliumbasedrug developmentend of lifeimmortalized cellin vivoin vivo Modelinfluenzavirusinsightnovelpathogenpreventreceptorrespiratory
项目摘要
DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) infection is the most common cause of hospital admission for children, and in the elderly population RSV is the second most common cause of death from respiratory infection after influenza virus. Most studies of RSV infection on the cellular level have been performed in cultured, immortalized cells. In these cells, RSV binds to heparan sulfate (HS), a complex oligosaccharide on the cell surface, as its primary receptor to initiate infection. In primary, well differentiated human airway epithelial (HAE) cultures, an excellent model for the airway cells that RSV targets, RSV infects only ciliated cells and only via the apical surface. But this surface has no detectable HS. RSV must, therefore, use a different receptor to enter these cells. The goals of this project are to identify that receptor and the site on the RSV attachment protein that binds to it. Both will provide novel targets for the development of novel antiviral agents against RSV.
描述(由申请人提供):呼吸道合胞病毒(RSV)感染是儿童入院的最常见原因,而在老年人群中,RSV 是继流感病毒之后第二大常见的呼吸道感染死亡原因。大多数细胞水平上 RSV 感染的研究都是在培养的永生化细胞中进行的。在这些细胞中,RSV 与硫酸乙酰肝素 (HS) 结合,硫酸乙酰肝素是细胞表面的一种复杂寡糖,作为其启动感染的主要受体。在原代、分化良好的人气道上皮 (HAE) 培养物中,RSV 是 RSV 靶向的气道细胞的绝佳模型,RSV 仅感染纤毛细胞,并且仅通过顶端表面感染。但该表面没有可检测到的 H2S。因此,RSV 必须使用不同的受体才能进入这些细胞。该项目的目标是识别该受体以及 RSV 附着蛋白上与其结合的位点。两者都将为开发针对 RSV 的新型抗病毒药物提供新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark E. Peeples其他文献
Mark E. Peeples的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark E. Peeples', 18)}}的其他基金
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity
具有优化安全性和免疫原性的 RSV 减毒活疫苗
- 批准号:
9133254 - 财政年份:2015
- 资助金额:
$ 40.9万 - 项目类别:
Respiratory Syncytial Virus Targeting of the Human Airway Epithelium
靶向人类气道上皮的呼吸道合胞病毒
- 批准号:
10542423 - 财政年份:2011
- 资助金额:
$ 40.9万 - 项目类别:
Respiratory Syncytial Virus Targeting of the Human Airway Epithelium
靶向人类气道上皮的呼吸道合胞病毒
- 批准号:
8386554 - 财政年份:2011
- 资助金额:
$ 40.9万 - 项目类别:
Respiratory Syncytial Virus Targeting of the Human Airway Epithelium
靶向人类气道上皮的呼吸道合胞病毒
- 批准号:
8239169 - 财政年份:2011
- 资助金额:
$ 40.9万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 40.9万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 40.9万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 40.9万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 40.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 40.9万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 40.9万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 40.9万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 40.9万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 40.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 40.9万 - 项目类别:














{{item.name}}会员




